Merck to acquire cancer drug maker Peloton Therapeutics for $1.05Bn
Category: #health  By Mateen Dalal  Date: 2019-05-23
  • share
  • Twitter
  • Facebook
  • LinkedIn

Merck to acquire cancer drug maker Peloton Therapeutics for $1.05Bn

The acquisition would help Merck strengthen its presence in the renal cell carcinoma space and support its cancer drug portfolio.

U.S. pharmaceutical conglomerate, Merck & Co. Inc. has recently agreed to purchase Dallas based Peloton Therapeutics Inc. for an estimated $1.05 billion in cash, acquiring access to the firm’s lead kidney cancer treatment portfolio.

For the record, Peloton is a clinical-stage biotech firm focused on cancer treatments. The company’s business hinges on two drugs that are designed to block a transcription factor dubbed hypoxia-inducible factor-2 alphaα (HIF-2α) which, among other things, regulates the way a body responds to low oxygen levels. 

According to sources, Peloton’s acquisition could strengthen Merck’s presence in the renal cell carcinoma field and support its cancer drug portfolio. Besides, Merck’s famous immunotherapy Keytruda was also been approved recently in the U.S. for treating renal cell cancer.

Speaking on the move, Dr. Roger M. Perlmutter, Merck Research Laboratories President, said that the acquisition validates the company’s strategy in pursuing new therapeutic candidates based on highly promising and innovative research.

He said that that scientists at Peloton have applied their know-how in HIF-2α biology to develop PT2977, which has shown commendable activity in the treatment of renal cell carcinoma. Perlmutter added that Merck is furthering this late-stage asset as part of its oncology R&D program.

Reportedly, from an older mid-stage trial, which included patients whose cancer had spread despite being treated with at least one therapy, around 24% of them subjected to Peloton’s treatment showed at least 30% shrinkage of targeted lesions.

Positive about its pipeline, Peloton was earlier seeking to go public and had also allotted a pricing range of $15 to $17 per share for its initial public offering recently. Nevertheless, with Merck’s recent deal, Peloton shareholders could be eligible to acquire a further $1.15 billion on attaining certain regulatory and sales milestones.

The deal is expected to close in the third quarter of 2019. Meanwhile, shares of Merck were reported to have gained 34.7% in the last 12 months, while the S&P 500 gained 3.9%.

Source Credit: https://www.reuters.com/article/us-merck-co-deals/merck-buys-peloton-to-expand-its-kidney-cancer-treatment-portfolio-idUSKCN1SR136

https://www.marketwatch.com/story/merck-to-acquire-peloton-therapeutics-for-upfront-payment-of-105-billion-in-cash-2019-05-21

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

Applied Therapeutics unveils Phase 1/2 trial of Galactosemia treatment
Applied Therapeutics unveils Phase 1/2 trial of Galactosemia treatment
By Mateen Dalal

Galactosemia patients are in urgent need of treatment options and the company is committed to advancing AT-007 through clinical development Reports confirm that Applied Therapeutics Inc. has recently unveiled the initiation of a Phase 1/2 clinical t...

Security concerns drive Microsoft to ban internal use of Slack, AWS
Security concerns drive Microsoft to ban internal use of Slack, AWS
By Mateen Dalal

Microsoft believes various versions of Slack do not offer sufficient controls to protect its intellectual property Microsoft has reportedly barred its more than 100,000 employees from using the free version of Slack. Apparently, Microsoft has come u...

Harley-Davidson inks deal to make smaller motorcycles in China
Harley-Davidson inks deal to make smaller motorcycles in China
By Mateen Dalal

The new bikes would have a 338cc engine, by far the smallest engine model Harley has ever made, and will be sold in China by late 2020. American motorcycle manufacturer Harley-Davidson has reportedly announced to have inked a partnership with C...